S. Irons

Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab

A. T. Freeman, M. Lesperance, D. Fenton, 2020, Translational lung cancer research.

Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.

A. T. Freeman, M. Lesperance, D. Fenton, 2019, Lung cancer.

Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort.

P. Truong, M. Lesperance, D. Ksienski, 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab.

A. T. Freeman, M. Lesperance, D. Fenton, 2020, Journal of geriatric oncology.

Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.

A. T. Freeman, M. Lesperance, D. Fenton, 2019, Current oncology.